Nextage Therapeutics Ltd
Nextage Therapeutics Ltd develops and commercializes in-vitro cancer diagnostic products and solutions worldwide. It offers CellDetect, a diagnostic platform for early cancer detection, including bladder cancer, cervical cancer, and prostate cancer. The company also provides BRONJ Test, a test for bisphosphonate-related osteonecrosis of the jaw. In addition, it offers gene expression, and biomark… Read more
Nextage Therapeutics Ltd - Asset Resilience Ratio
Nextage Therapeutics Ltd (MCTC) has an Asset Resilience Ratio of 0.71% as of June 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2019)
This chart shows how Nextage Therapeutics Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Nextage Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA35.00K | 0.71% |
| Total Liquid Assets | ILA35.00K | 0.71% |
Asset Resilience Insights
- Limited Liquidity: Nextage Therapeutics Ltd maintains only 0.71% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Nextage Therapeutics Ltd Industry Peers by Asset Resilience Ratio
Compare Nextage Therapeutics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Lavipharm S.A
AT:LAVI |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Medicon Hellas S.A.
AT:MEDIC |
Drug Manufacturers - Specialty & Generic | 32.11% |
|
Tsumura & Co
MU:TSUA |
Drug Manufacturers - Specialty & Generic | 0.14% |
Annual Asset Resilience Ratio for Nextage Therapeutics Ltd (2002–2019)
The table below shows the annual Asset Resilience Ratio data for Nextage Therapeutics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 2.03% | ILA122.00K | ILA6.01 Million | -0.20pp |
| 2018-12-31 | 2.23% | ILA122.00K | ILA5.48 Million | +1.24pp |
| 2017-12-31 | 0.98% | ILA122.00K | ILA12.39 Million | -0.28pp |
| 2016-12-31 | 1.27% | ILA145.00K | ILA11.43 Million | +0.17pp |
| 2015-12-31 | 1.10% | ILA145.00K | ILA13.14 Million | +0.25pp |
| 2014-12-31 | 0.85% | ILA145.00K | ILA17.00 Million | +0.06pp |
| 2012-12-31 | 0.79% | ILA182.00K | ILA23.07 Million | -18.23pp |
| 2011-12-31 | 19.02% | ILA4.19 Million | ILA22.05 Million | -62.16pp |
| 2010-12-31 | 81.18% | ILA12.88 Million | ILA15.86 Million | +74.43pp |
| 2003-12-31 | 6.74% | ILA843.00K | ILA12.50 Million | -0.39pp |
| 2002-12-31 | 7.14% | ILA1.23 Million | ILA17.25 Million | -- |